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Abstract
Background: The aim of this study was to provide a model-based analysis of the pharmacokinetics
of remifentanil in infants and children undergoing cardiac surgery with cardiopulmonary bypass
(CPB).
Methods: We studied nine patients aged 0.5 to 4 years who received a continuous remifentanil
infusion via a computer-controlled infusion pump during cardiac surgery with mildly hypothermic
CPB were studied. Arterial blood samples taken prior to, during and after CPB were analyzed for
remifentanil concentrations using a validated gas-chromatographic mass-spectrophotometric assay.
We used population mixed-effects modeling to characterize remifentanil pharmacokinetics. The
final model was evaluated by its predictive performance.
Results: The pharmacokinetics of remifentanil was described by a 1-compartment model with
adjustments for CPB. Population mean parameter estimates were 1.41 L for volume of distribution
(V) and 0.244 L/min for clearance. V was increased during CPB and post-CPB to 2.41 times the pre-
CPB value. The median prediction error and the median of individual median absolute prediction
error were 2.44% and 21.6%, respectively.
Conclusion: Remifentanil dosage adjustments are required during and after CPB due to marked
changes in the V of the drug. Simulations indicate that a targeted blood concentration of 14 ng/mL
is achieved and maintained in 50% of typical patients by administration of an initial dose of 18 μg
remifentanil followed by an infusion of 3.7 μg/min before, during and post-CPB, supplemented with
a bolus dose of 25 μg given at the start of CPB.
Background
Remifentanil is a selective μ-opioid receptor agonist that
produces intense analgesia of rapid onset and ultra short
duration [1]. Accordingly, remifentanil provides the ben-
efits of a high-dose opioid anesthetic during cardiac sur-
gery (e.g. minimal sympathetic response to tracheal
intubation and sternotomy) while allowing tracheal extu-
bation in the operating room immediately following sur-
gery.
CPB may alter the pharmacokinetics of anesthetic agents
due to hypothermia, hemodilution, exclusion of the lungs
from the circulation and a decrease in plasma protein con-
centration [2]. However, the impact of CPB on the phar-
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macokinetics of remifentanil in infants and children has
not been fully investigated. Davis et al [3] studied the
pharmacokinetics of remifentanil before and after CPB in
12 pediatric patients undergoing repair of an atrial septal
defect. They found that after CPB clearance values
increased by 20% (from 38.7 ± 9.6 to 46.8 ± 14 mL/min/
kg), without a meaningful change in the coefficient of var-
iation. The authors concluded that the pharmacokinetics
of remifentanil is predictable following CPB. However,
this study failed to investigate the pharmacokinetics of a
remifentanil infusion during CPB.
An unanticipated decrease in remifentanil plasma concen-
tration during CPB may be detrimental. Significant intra-
operative stress responses, postoperative complications
and increased mortality have been reported in infants
receiving inadequate analgesia during cardiac surgery
[4,5]. Therefore, the aim of our investigation was to deter-
mine the effect of CPB on the pharmacokinetics of
remifentanil in infants and children during all phases of
cardiac surgery using mixed-effect modeling in order to
inform accurate dosage titration.
Methods
Nine infants and children scheduled for open-heart sur-
gery requiring CBP were studied after Institutional Review
Board approval and written informed parental consent
were obtained. These patients were part of a prospective,
randomized, controlled clinical trial to define the opioid
analgesic requirement after a remifentanil-based anes-
thetic with or without spinal anesthetic blockade (SAB).
Inclusion criteria were age 3 months to 6 years and
planned tracheal extubation in the operating room after
surgery (e.g. absence of severe pulmonary hypertension or
heart failure). Exclusion criteria were contraindication to
SAB and failure to obtain informed consent. Details of the
study have been described elsewhere [6].
Premedication was given to patients over the age of 1 year
(midazolam 0.5–0.75 mg/kg by mouth). Following place-
ment of standard monitors, anesthesia was induced with
sevoflurane and tracheal intubation was performed after
administration of rocuronium. Anesthesia was main-
tained with isoflurane 0.3% and a continuous infusion of
remifentanil with or without SAB with tetracaine (0.5 –
2.0 mg/kg) and morphine (0.007 mg/kg). Remifentanil
was infused with a target-controlled infusion system pro-
grammed with parameters obtained from Minto et al [7]
to maintain a constant predicted blood target concentra-
tion of 1–8 ng/mL. Remifentanil infusion rates were
adjusted according to the judgment of the investigator in
order to achieve a target mean arterial blood pressure (i.e.
50 to 60 mm Hg). Arterial blood pressure, heart rate, oxy-
gen saturation and dosing history of remifentanil were
continuously recorded during the surgery. At the comple-
tion of surgery, tracheal extubation was performed in the
operating room and supplemental analgesia was achieved
with fentanyl 0.003 mg/kg IV every 10 minutes as needed.
Prior to CPB, anticoagulation was established with an ini-
tial bovine heparin dose of 400 U/kg and additional
heparin was administered during CPB to maintain celite
activated clotting time (ACT) greater than 480 seconds.
Non-pulsatile CPB was performed with a hollow fiber
membrane oxygenator (Terumo CapioxC RX05, Terumo
Cardiovascular Systems, Ann Arbor, MI), uncoated poly-
vinyl chloride bypass tubing and cannulae, and non-
occlusive roller pump. The circuit was primed with nor-
mal saline, 25% albumin, mannitol, sodium bicarbonate,
calcium chloride, methylprednisolone (30 mg/kg) and
heparin. CPB circuit volumes were 450 mL for patients <
10 kg, 800 mL for patients 10–15 kg and 1,000–1,200 mL
for patients > 15 kg. Banked packed red blood cells and
fresh frozen plasma were added to achieve a hematocrit of
about 30% during initiation of CPB. CPB flow rates were
200 mL/kg for infants with body weight less than 5 kilo-
grams (kg), 150 mL/kg for those between 5 and 9 kg and
125 mL/kg for those between 10 and 17 kg; flows of 2.4
L/m2 were used in children over 17 kg. An initial dose of
cardioplegia of 30 mL/kg was given, followed by 10 mL
every 10–20 minutes thereafter. Hypothermia (28 –
32°C) was induced in all patients and blood gases were
regulated according to alpha-stat regimen. Myocardial
preservation was achieved using cold crystalloid cardio-
plegia. Target post-CPB hematocrit values varied from
35% to 50% depending upon the patient's cardiac and
respiratory status. Antifibrinolytic agents were not admin-
istered.
Conventional ultra-filtration (CUF) was performed
throughout CPB to achieve a filtrate volume of at least 120
mL/kg. Fluids (crystalloid, red blood cells or fresh frozen
plasma) were added when necessary to provide sufficient
volume in the CPB circuit to permit ultrafiltration. The
polysulfone hemofilter used (MinntechC HPH 400; Min-
ntech Corporation, Minneapolis, MN) employs hollow
fiber technology and is rated to have a filtration cut-off to
particles greater than 65,000 Daltons (Da). A transmem-
brane pressure gradient of at least 200 mm Hg was applied
during ultrafiltration. After the addition of blood prod-
ucts, hemofiltration of the CPB circuit prime was per-
formed before CPB to adjust pH and electrolyte
concentrations and to remove inflammatory mediators.
Filtrate volume from pre-CPB filtration ranged from 100
mL to 200 mL.
Arterio-venous modified ultra-filtration (MUF) was initi-
ated on selected patients after separation from CPB
according to the surgeons' preferences. Blood from the
aortic cannula and from the CPB circuit venous reservoir
was pumped through the hemofilter and was then
warmed by a coiled heat exchanger (Medtronic MYO-BMC Anesthesiology 2009, 9:5 http://www.biomedcentral.com/1471-2253/9/5
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therm XPR cardioplegia delivery system, Medtronic Inc.,
Minneapolis, MN) and returned via the cardioplegia cir-
cuit to the venous cannulae. Infusion rates were adjusted
to maintain appropriate central venous and/or left atrial
pressures. MUF was terminated when red cell salvage of
circuit contents was judged by the perfusionist to be com-
plete.
Whole blood arterial samples for assay of remifentanil
concentrations were obtained before and 5 min after each
adjustment of the infusion rate. No samples were taken
prior to the initiation of remifentanil infusion. Samples
were initially aspirated into heparinized syringes, imme-
diately transferred to tubes containing 50% citric acid to
inactivate plasma esterases and kept frozen at -20°C.
Remifentanil concentrations were determined using a val-
idated gas-chromatographic mass-spectrophotometric
(GC-MS) assay with inter-, intraassay coefficients of varia-
tion and lower limit of quantification of 4.6%, 4.0% and
0.5 ng/mL, respectively [3].
Pharmacokinetic data were analyzed via a population
approach implemented using the NONMEM V program
(Globomax LLC, Hanover, MD) with PREDPP subrou-
tines ADVAN1 TRANS2 [8]. First-order conditional esti-
mation with interaction was used for the estimation of
model parameters. One- and two- compartmental models
were evaluated as the structural pharmacokinetic models.
For the purpose of this analysis, the study was subdivided
into two time intervals: CPB and non-CPB, where CPB
was defined as the period between initiation and termina-
tion of CPB and non-CPB was defined as both the periods
from the start of the remifentanil infusion until CPB was
initiated and the periods between termination of CPB and
completion of blood sampling. Relationships between
the categorical covariates such as CPB, gender, application
of SAB, MUF and a pharmacokinetic model parameter p
were modeled as shown below:
where TV(P) refers to the typical value of the pharmacok-
inetic parameter for a patient with the reference covariate
value and θcovariaterefers to the estimated fractional change
in the typical value of the pharmacokinetic parameter for
the investigated covariate.
Allometric scaling was implemented to assess the influ-
ence of body size on the pharmacokinetic parameters [9].
where Pi is the parameter in the ith individual, Wi is the
weight in the ith individual, and Pstd is the parameter in an
individual with a weight Wstd of 70 kg. The PWR exponent
was 0.75 for CL and 1 for volume of distribution. The
effects of continuous covariates such as age, body weight
were assessed for their influence on the pharmacokinetic
parameters according to the following equation:
where TV(P) is the typical value of P for a patient with the
mean covariate value and θcovariate is the estimated effect
for the covariate on P. In addition, the effect of body tem-
perature on CL of remifentanil was modeled both as a lin-
ear function and an exponential function:
where TVCL is the model predicted value for CL given the
value for temperature. θCL represents the population cen-
tral tendency for CL. θCL, TEMP represents a parameter
quantifying the effect of temperature on CL, and TEMP is
the body temperature in °C.
Using the basic pharmacokinetic model, each potential
covariate was separately incorporated and tested for statis-
tical significance by use of the NONMEM objective func-
tion and the standard errors of the parameters. The
likelihood ratio test at the significance level α = 0.01 was
used to discriminate between alternative hierarchical
models. The α level of 0.01 corresponds to a reduction of
6.64 (χ2, p < 0.01; 1 degree of freedom) in the minimum
objective function when 1 parameter is added to the
model and was used to examine significance. In addition
to the minimum objective function, diagnostic goodness-
of-fit plots were used for model building and selection. If
more than one significant covariate was found, the covari-
ate model causing the largest decrease in objective func-
tion was chosen as a basis to explore the influence of
additional covariates sequentially with the use of the same
criteria.
An exponential variance model (Equation 7) was used to
describe the inter-individual variability in the pharmacok-
inetic parameters with the assumption that the parameters
are log-normally distributed:
where pi refers to the individual value of the respective
pharmacokinetic parameter in the ith individual, θ is the
typical value of the parameter, and exp(ρi) expresses the
p TV P for reference covariate = () (1)
p TV P for investigated covariate covariate =⋅ ()q
(2)
PP is t d =× ()
Wi
Wstd
PWR (3)
P TV P Covariate mean covariate
covariate =⋅ ()( / )
q
(4)
TVCL =+ − qq CL CL TEMP TEMP . () 28 (5)
TVCL =⋅ − qq CL CL TEMP TEMP exp( *( )) . 28 (6)
pi i =⋅ qh exp( ) (7)BMC Anesthesiology 2009, 9:5 http://www.biomedcentral.com/1471-2253/9/5
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random difference between θ and pi. Values of ηi are
assumed to be independently multi-variate and normally
distributed, with mean zero and diagonal variance-covar-
iance matrix Ω with diagonal elements (ω1
2,..., ωm
2).
A proportional and combined additive and proportional
models for residual variability for pharmacokinetic obser-
vations were evaluated (Equations 8 and 9).
where Cij is the jth remifentanil concentration of the ith
individual predicted by the pharmacokinetic model, and
Yij is the measured remifentanil concentration. The resid-
ual departure of Yij from Cij is represented by εij. Values of
εij are assumed to be independently and normally distrib-
uted, with mean zero and variance σ2.
The likelihood ratio test at the significance level α = 0.01
was used to discriminate between hierarchical models.
This corresponds to a decrease of ≥ 6.635 (one parameter
difference) in the minimum objective function (-2 × loga-
rithm of the likelihood of the results), as the difference in
objective function between hierarchical models is approx-
imately χ2distributed. When more than 1 parameter was
added, a decrease in the objective function of ≥ 9.210,
11.345 and 13.277 was needed at the significance level of
α = 0.01 for 2, 3 and 4 degrees of freedom, respectively.
Predictive performance of the final pharmacokinetic
model was evaluated by examining the prediction error
(PE), which is a retrospective analysis of the quality of fit
[10]. PE is defined as follows:
where Cm is the measured remifentanil concentration and
Cp is the predicted remifentanil concentration. The intra-
subject bias (inaccuracy) and precision of the predictions
were assessed by quantifying the median prediction error
(MDPE) (median of all MDPEi) and median absolute
weighted residual (MDAPE) (median of all MDAPEi),
respectively. MDPE for the ith patient is given by:
where Ni is the number of samples obtained for the ith
patient and j is the sample number for the ith patient.
MDAPE for the ith patient is given by:
where Ni is the number of samples obtained for the ith
patient and j is the sample number for the ith patient.
Model goodness-of-fit was checked by using diagnostic
plots such as the PE over time plot and observed versus
predicted plot. The final optimal model was selected
based on the objective function, the predictive accuracy
and goodness-of-fit plots.
The predictive performance of the population pharma-
cokinetic parameters of remifentanil by Minto et al [7]
used to program STANPUMP was assessed by the predic-
tion error (PE) and residual error plot. The intra-subject
bias and precision of the predictions were assessed by
quantifying the MDPE and MDAPE, respectively. The
residual error plot is the percentage ratio of the measured
concentration over the predicted concentration versus
time.
We assessed the stability and robustness of the final mod-
els via bootstrapping [11]. We obtained a new replication
of original dataset (a bootstrap sample) by 1000 random
draws of individual subject's data (with replacement)
from the original dataset and we fitted the final model to
each new dataset. We compared the final model parame-
ter estimates to the mean of the parameter estimates
obtained from 1000 bootstrap replicates of the final
model.
Simulation was also performed using parameters of our
final pharmacokinetic model to determine the optimal
infusion and loading doses of remifentanil needed during
the different intervals of cardiac surgery needed to main-
tain average concentration of 14 ng/mL. A typical patient
of weight 11.4 kg and 60 min of surgery were assumed
before and after 60 min of CPB for simulation purposes.
Results
Table 1 lists patient demographic data. Mean total infu-
sion time was 218 ± 77.9 min (mean ± standard devia-
tion, SD). The mean total dose of 721 ± 362 μg (mean ±
SD) remifentanil and mean weight-normalized total dose
of 65.0 ± 32.6 μg/kg (mean ± SD) remifentanil were
administered. Remifentanil concentrations during pre-
CPB, intra-CPB and post-CPB were 13.8 ± 7.80 ng/mL
(mean ± SD), 12.7 ± 6.39 ng/mL (mean ± SD) and 11.7 ±
7.03 ng/mL (mean ± SD), respectively. No samples meas-
ured were below the lower limit of quantification. The
infusion rates required to control MAP during pre-, intra-
and post-CPB were 0.264 ± 0.205 μg/min/kg (mean ±
SD), 0.339 ± 0.120 μg/min/kg (mean ± SD) and 0.321 ±
0.175 μg/min/kg (mean ± SD), respectively. A total of 105
samples from all 9 patients were available for modeling. A
total of 34, 23 and 48 samples were obtained during pre-
, intra- and post-CPB periods, respectively. The median
number and range (in parentheses) of samples obtained
YC ij ij ij =+ () 1 e (8)
YC ij ij ij ij =++ () ,, 1 12 ee (9)
PE =
−
×
()
%
Cm Cp
Cp
100 (10)
MDPE median PE N ii j i j == {, , , , , } 123K (11)
MDAPE median PE N i == {| |, , , , , } ij i j 123K
(12)BMC Anesthesiology 2009, 9:5 http://www.biomedcentral.com/1471-2253/9/5
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during pre-, intra- and post-CPB were 3 (1–9), 3 (1–5)
and 7 (3–8), respectively.
A small decrease in the objective function of 1.33 is asso-
ciated with the use of a two-compartment model com-
pared with a one-compartment model. Therefore, a one-
compartment model was used as the structural model for
estimating CPB-adjusted models. A small decrease in the
objective function of 0.275 is associated with the use of a
combined proportional and additive residual error model
compared with a proportional residual error model.
Therefore, a proportional residual error model was used.
Use of allometric scaling did not result in improvement of
the fit as evidenced by a small decrease of 1.162 units in
the objective function. The model incorporating changes
in V during CPB and post-CPB produced the greatest drop
in objective function of 15.928 and was statistically signif-
icantly (p < 0.01) better than the one-compartment
model. Allowing changes in CL during the CPB did not
result in a statistical improvement in fit. Therefore, the V-
adjusted one-compartment model is used as the final
pharmacokinetic model for remifentanil. The basic good-
ness-of-fit plots for the population pharmacokinetic
model of remifentanil are shown in Figure 1.
Table 2 shows the volume and clearance of the final pop-
ulation pharmacokinetic model of remifentanil and the
stability of the parameters using the bootstrap resampling
procedure. The data supported changing only V with the
onset of CPB and post-CPB. With the onset of CPB and
post-CPB, V increased 2.41 times of its non-CPB value.
The final model estimates were similar to that obtained
from 1000 bootstrap replicates of the original dataset,
indicating stability of the population pharmacokinetic
model. Final weight-normalized population parameter
estimates (obtained by normalizing the final population
mean estimates with the average weight) are shown in
Table 3. For the final pharmacokinetic model, the MDPE
for all data points was 2.44% and the MDPE for individ-
ual patients ranged from – 45.0% to 14.3%. The plot of PE
over time shows random distribution of PEs about the
line of zero PE and ranges between -100 to 100% (not
shown). MDAPE for the individual patients ranged from
8.11% to 61.2% and the median individual MDAPE is
21.6%. Figure 2 shows the worst, median and best fits (as
assessed by the MDAPEs) for the final pharmacokinetic
model.
The predictive performance of the remifentanil target-
infusion system incorporating the population pharma-
cokinetic parameters for remifentanil of Minto et al [7]
showed a poor performance with both MDPE and
MDAPE of 256%. The residual error plot showed that the
concentrations were consistently under-predicted with
time (Figure 3).
Simulation results (Figure 4) showed that an initial load-
ing dose of 18 μg and a 3.7 μg/min continuous infusion
of remifentanil before, during and after CPB and a bolus
dose of 25 μg given at the start of CPB, achieves and main-
tains a targeted blood concentration of 14 ng/mL in 50%
of the patients. 60% of the simulated patients would
achieve blood concentrations between 8.31 to 23.1 ng/
mL.
Discussion
Remifentanil is a widely used analgesic agent during car-
diac surgery but little is known about its pharmacokinet-
Table 1: Patient demographics
Value
Gender (male/female) 5/4
Age (year)† 2.19 (0.5–4.0)
Weight (kg)† 11.4 (6.4–14.7)
Anesthetic technique
SAB+REMI/REMI 3/6
Procedures
Atrial septal defect repair 6
Glenn shunt 2
Supraventricular aortic stenosis repair 1
Resection of pulmonary valve leaflets 1
Reconstruction of pulmonary valve 1
Reduction plasty of aneurysm of main pulmonary artery 1
Division of ductus arteriosus 1
Modified ultrafiltration
Yes/no 4/5
Duration of CPB (min)* 75.0 ± 33.3
† Values are mean (range)
*Values are mean ± standard deviation
Abbreviations: SAB = spinal anesthetic blockade, REMI = remifentanilBMC Anesthesiology 2009, 9:5 http://www.biomedcentral.com/1471-2253/9/5
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ics in infants and children undergoing CPB. We found
that a 1-compartment pharmacokinetic model adjusted
for CPB performed well. The relatively sparse sampling
scheme we adopted in this study precludes the develop-
ment of a multi-compartment model. Although a limited
number of blood samples were collected during CPB, use
of a V-adjusted CPB pharmacokinetic model produced a
statistically significant improvement (p < 0.01) over the
basic 1-compartment model.
The results of our study may be compared with those of
other investigators studying the pharmacokinetics of
remifentanil in pediatric and adult patients undergoing
CPB [3,12,13] (Table 3). The population mean volume of
distribution at steady-state (Vss) at pre-CPB, 124 mL/kg,
estimated by our final CPB-adjusted pharmacokinetic
model in this study is smaller than those previously
reported in pediatric patients of 235 mL/kg [3,12,13].
However, the population mean Vss at CPB and post-CPB,
298 mL/kg is similar to the post-CPB value of 235 mL/kg
reported by Davis et al [3]. The relatively small population
mean CL estimated in this study (21.4 mL/kg/min) maybe
due to differences in patient characteristics from studies
previously reported such as cardiac output, which has
been reported to be a factor influencing the CL of remifen-
tanil [14]. The elimination half-lives of remifentanil were
similar to those determined by previous investigators
[3,12,13].
The results of our analysis indicate that V of remifentanil
increases by 141% with the institution of CPB and
remained increased during post-CPB. This is similar to the
findings of Michelsen et al who found that the volume of
distribution of remifentanil increased by 86% with insti-
Basic goodness-of-fit plots for the population pharmacokinetic model Figure 1
Basic goodness-of-fit plots for the population pharmacokinetic model. The line of identity is presented. (Upper left 
and right panels) Population and individual predicted vs. observed remifentanil concentrations. (Lower left and right panels) 
Weighted residuals vs. mean predicted and time.
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tution of CPB, and remained increased during post-CPB
[12] in adult patients. Hemodilution due to the CPB
prime is the most likely reason for the increase in V. The
141% increase in the V of remifentanil in infants and chil-
dren during and post- CPB compared to pre-CPB is higher
than the expected range as the average CPB prime volume
for patients between 10–15 kg is about 800 mL. The dis-
crepancy may be due to drug adsorption to CPB circuit or
additional sources of extracellular fluid secondary to ren-
nin and atrial natriuretic peptide release as a result of non-
pulsatile renal blood flow during CPB [15]. Our results are
also similar to the findings of Davis et al [3] who esti-
mated similar volumes of distribution of remifentanil
during post-CPB in children undergoing cardiac surgery.
The CL of remifentanil was found to be unaffected by CPB
which is similar to that reported by Michelsen et al [12].
Contrary to that reported by Michelsen et al [12] and Rus-
sell et al [13], temperature is not found to be a significant
factor affecting the CL of remifentanil in this study. This
may be due to a limited range of temperature (33.7–
38.0°C) and mild hypothermia encountered in the
majority of the patients during CPB. Moreover, the rela-
tively short duration of CPB may have hindered the ability
to identify changes in CL during bypass. The changes in
the elimination half-lives (t1/2β) of remifentanil during
the CPB and non-CPB follow the same trend and magni-
tude as the V (Table 3), suggesting that the pharmacoki-
netic advantage of short recovery from anesthesia post-
CPB is modified in pediatric cardiac surgical patients.
MUF, first described by Naik et al [16], reduces total body
water, induces hemoconcentration and improves postop-
erative recovery in children after open heart surgery
[16,17]. However, information is lacking regarding how
MUF affects the pharmacokinetics of remifentanil in pedi-
atric patients. Our study shows that MUF has little effect
on the pharmacokinetics of remifentanil in pediatric car-
diac patients.
The population model is able to predict blood concentra-
tions accurately and with good precision as evidenced by
a small MDPE and median individual MDAPE of 2.44%
and 21.6%, respectively. These, together with the results
of the diagnostic plots which showed random uniform
scatter around the identity line (Figure 1) and an absence
of bias, indicates the suitability of the final pharmacoki-
netic model as a basis for pharmacokinetic modeling. On
the other hand, the poor predictive performance of the
remifentanil target-infusion system incorporating the
population pharmacokinetic parameters for remifentanil
of Minto et al [7] developed using data from adult
patients does not meet the criteria for clinical utility [18]
and thus has a limited utility in pediatric patients.
One reason for pharmacokinetic analysis is to determine
an effective dosing regimen. Therapeutic blood concentra-
tions of remifentanil range from 1.5 ng/mL for sedation to
50 ng/mL for anesthetic effects in both humans and dogs
[1,12,19,20]. We selected an average concentration of 14
ng/mL is selected as the therapeutic concentration for the
Best, median and worst pharmacokinetic predictions for  remifentanil based on the final pharmacokinetic model (meas- ured concentration (black square), ---- population predicted  concentration, —— individual predicted concentration and  ... infusion rate) Figure 2
Best, median and worst pharmacokinetic predictions 
for remifentanil based on the final pharmacokinetic 
model (measured concentration (black square), ---- 
population predicted concentration, —— individual 
predicted concentration and ... infusion rate). Arrows 
indicate the start and stop times of cardio-pulmonary bypass 
(CPB).
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design of an effective dosing regimen for remifentanil.
This concentration was chosen as a result of pharmacoki-
netic-pharmacodynamic analysis of the hypotensive effect
of remifentanil in pediatric patients undergoing cranio-
plasty by the authors, which shows that this concentration
leads to a 30% reduction in mean arterial pressure from
the baseline. For a typical patient, an initial loading bolus
dose of 18 μg remifentanil and a 3.7 μg/min continuous
infusion before, during and post-CPB, supplemented with
a bolus dose of 25 μg given at the start of CPB, achieves
and maintains a targeted blood concentration of 14 ng/
mL in 50% of the patients. The supplemental bolus dose
is needed to compensate for the increase in V during CPB.
Because the population model was based on pediatric
patients with mild hypothermia during CPB, this dosing
recommendation may not apply to conditions of moder-
ate to deep hypothermia during CPB as low body temper-
ature has been reported to be a factor reducing CL during
CPB [12,13].
One limitation of our pharmacokinetic modeling is our
model's failure to account for drug removed from the CPB
circuit post-CPB. This problem can be solved by treating
the CPB process as a separate compartment from the cen-
tral compartment and the CPB compartment turn on/off
when CPB starts/stops. Unfortunately, the relatively
sparse sampling schedule in this study precludes using a
multi-compartment model and the use of this approach
to correct for the removal of drug from the system after
CPB. Thus, we adopted an approach commonly reported
in the literature of allowing the pharmacokinetic parame-
ters to change during and after CPB for modeling.
Conclusion
We developed a CPB-adjusted pharmacokinetic model for
remifentanil dosing in infants and children undergoing
cardiac surgery with mild hypothermic CPB. Because the
V of remifentanil was markedly increased during CPB and
remained elevated post-CPB, a supplemental bolus dose
of remifentanil is required during CPB in pediatric cardiac
anesthesia. Studies are warranted to determine the phar-
macokinetics of remifentanil in infants and children dur-
ing moderate and deep hypothermia to determine how
further temperature decreases affect pharmacokinetic
parameters. Such future studies should lead to safer more
Table 2: Population pharmacokinetic parameters and the stability of the parameters using the bootstrap resampling procedure.
Original data 1000 bootstrap replicates
Mean estimate 95% C.I. Mean estimate 95% C.I.
Structural model
Volume of distribution during pre-bypass, V (L) 1.41 0.491, 2.33 1.57 0.943, 2.81
Clearance, CL (L/min) 0.244 0.197, 0.291 0.249 0.201, 0.300
Effect of bypass and post-bypass on VPRE 2.41 1.60, 3.22 2.26 1.66, 2.96
Inter-individual variability ω CL (%) 33.8 19.7, 43.5 31.3 16.0, 41.1
Residual unexplained variability
Proportional residual error, coefficient of variation (%) 43.8 25.1, 56.7 42.5 29.0, 57.3
C.I., confidence interval
Table 3: Pharmacokinetic parameter estimates of remifentanil in pediatric patients undergoing cardiac surgery.
This studya Pediatricb Adultsc Adultsc Pediatricb Adultsd
Pre-CPB CPB Post-CPB Pre-CPB CPB Post-CPB
Volumes (mL/kg)
Vc 124 298 298 72.7 41.8 (23–61) 65.9 (22.6–89.0) 83.5 22.6
Vd
ss 124 298 298 235 1006 (245–1767) 344 (246–456) 235 456
Clearances (mL/min/kg)
CL 21.4 21.4 21.4 38.7 32.5 (32–33) 31 (25–35) 46.8 33
Q N.A. N.A. N.A. 25.5 29.6 (28.7–30.5) 39.8 (28.7–51.2) 37.0 28.7
Half-lives (min)
Distribution N.A. N.A. N.A. 0.73 0.43 (0.25–0.6) 0.55 (0.25–0.8) 0.63 0.25
Elimination 4.02 9.65 9.65 8.2 8.35 (6.4–10.3) 13.0 (7.2–19.8) 6.90 19.8
Abbreviations: CPB = cardiopulmonary bypass; Vc = central volume of distribution; Vd
ss = volume of distribution at steady-state; CL = clearance; Q 
= intercompartmental clearance, N.A. = not applicable
a Values are presented as population mean
b Values are presented as mean as reported by Davis et al [3]
c Values are presented as mean (range) values as reported by Michelsen et al and Russel et al [12,13]
d Values are presented as mean as reported by Michelsen et al [12]BMC Anesthesiology 2009, 9:5 http://www.biomedcentral.com/1471-2253/9/5
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consistently effective dosing of remifentanil in pediatric
patients undergoing cardiac surgery with CPB.
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